Skip to main content
Premium Trial:

Request an Annual Quote

Gates Foundation Gives UW $70 Million for Genome Sciences

NEW YORK, April 24 - The University of Washington has received a $70 million grant for genomics research from the Bill and Melinda Gates foundation, the foundation announced today.


This gift is the largest single private donation to an institution of higher education in the Northwest, the foundation said. Of the gift, $60 million will go toward construction of the UW schoolof Medicine's department of genome sciences, and the remaining $10 million will go toward global health programs related to genome sciences at UW.

The department of genome sciences will be housed in a 265,000 square-foot building on Seattle's

Pacific street
, at
15th Ave.


Along with $60 million from the Gates gift, the estimated $150 million in construction costs for the building will be funded with $12 million from the federal government, $10 million from the Whitaker foundation, and gifts from private sources. The building, designed by Anshen and Allen of Los Angeles, will include a mix of office and biomedical research laboratories. Construction is slated to begin this August, and the building and is expected to be partially open by fall 2005.


Human Genome project veteran Bob Waterston, who joined the UW in February as the William Gates III Chair in Biomedical sciences, said in a statement that the new building would blend key four elements important in future genomic research. "These elements are computational biology, technology development, experimental genetics and human genetics," Waterstson explained. "The UW building has been designed to encourage researchers to work collaboratively in ways that spur innovation and speed discoveries."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more